The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 16, 2021

Filed:

Mar. 20, 2018
Applicant:

Immunomedics, Inc., Morris Plains, NJ (US);

Inventors:

Thomas M. Cardillo, Cedar Knolls, NJ (US);

David M. Goldenberg, Mendham, NJ (US);

Assignee:

Immunomedics, Inc., Morris Plains, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61P 35/04 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61K 31/4353 (2006.01); A61K 33/24 (2019.01);
U.S. Cl.
CPC ...
A61K 47/6803 (2017.08); A61K 39/39558 (2013.01); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6857 (2017.08); A61K 47/6859 (2017.08); A61K 47/6863 (2017.08); A61P 35/04 (2018.01); C07K 16/18 (2013.01); A61K 31/4353 (2013.01); A61K 33/24 (2013.01); A61K 2300/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention relates to treatment of Trop-2 positive cancers with the combination of anti-Trop-2 ADC and a Rad51 inhibitor. Preferably the drug conjugated to the antibody is SN-38, and the ADC is sacituzumab govitecan. The ADC may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the combination of ADC and Rad51 inhibitor can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the combination is effective to treat cancers that are refractory to or relapsed from irinotecan or topotecan.


Find Patent Forward Citations

Loading…